Castle Biosciences, Inc.
Price Action
Technical Summary
CONSOLIDATINGCastle Biosciences, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 33), showing significant lag compared to the market leaders. Earnings growth of 46% provides fundamental context to the price action. Investors should exercise caution due to high volatility (59% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $24.49 | +1.07% | ABOVE |
| 50 SMA | $25.54 | -3.08% | BELOW |
| 100 SMA | $31.64 | -21.78% | BELOW |
| 150 SMA | $31.17 | -20.60% | BELOW |
| 200 SMA | $28.54 | -13.29% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is CSTL in an uptrend right now?
CSTL has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is CSTL overbought or oversold?
CSTL's RSI (14) is 47. The stock is in neutral territory, neither overbought nor oversold.
Is CSTL outperforming the market?
CSTL has a Relative Strength (RS) Rating of 33 out of 99. CSTL is currently lagging the broader market.
Where is CSTL in its 52-week range?
CSTL is trading at $24.75, which is 56% of its 52-week high ($44.28) and 34% above its 52-week low ($14.59).
How volatile is CSTL?
CSTL has a Beta of 0.88 and 52-week volatility of 59%. It's less volatile than the S&P 500 - generally more stable.